Wills Eye Conference

Wills Eye Conference

March 12, 2014
1 min read

Vitreomacular interface affects anti-VEGF injection intervals for AMD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PHILADELPHIA — The presence of vitreomacular interface disease appears to significantly affect anti-VEGF injection intervals for treatment of age-related macular degeneration, according to a study presented here.

Patients with or without vitreomacular adhesion (VMA) showed similar outcomes, with VMA patients requiring more intensive treatment with a diminished ability to lengthen intervals between injections, Samuel K. Houston III, MD, said at the Wills Eye Annual Conference.

“The anatomic factors may contribute to individual treatment responses and should be evaluated and considered in treatment decisions for neovascular AMD,” Houston said.

Samuel K. Houston III

The retrospective consecutive case series included 153 patients without VMA and 51 patients with VMA. Visual acuity and central retinal thickness were similar in both groups, with visual acuity improving in both groups as well. Both groups were followed for 2 years to assess interval extension of Avastin (bevacizumab, Genentech), Lucentis (ranibizumab, Genentech) or Eylea (aflibercept, Regeneron) injections.

“If we look at the injection intervals and the ability to extend these patients, patients with non-VMA were able to have a total number of injections of 7.3 at 1 year and 5.5 at year 2, whereas the VMA [group] required more frequent injections, requiring 8.3 in year 1 and 6.67 in year 2,” Houston said.

The longest interval extension occurred in the non-VMA group and was statistically significant, Houston said.

Disclosure: Houston has no relevant disclosures.